Clinical data on the use of immune checkpoint inhibitor–based treatment approaches for patients with early or intermediate-stage HCC
Optimal, individualized therapy approaches using immune checkpoint inhibitor–based regimens for patients with advanced or metastatic HCC, as clinically appropriate
Strategies to identify and mitigate unique adverse events associated with immune checkpoint inhibitor therapy in patients with HCC